Research ArticleArticle
Efficacy and Limitation of Infliximab Treatment for Children with Kawasaki Disease Intractable to Intravenous Immunoglobulin Therapy: Report of an Open-label Case Series
Masaaki Mori, Tomoyuki Imagawa, Ryoki Hara, Masako Kikuchi, Takuma Hara, Tomo Nozawa, Takako Miyamae and Shumpei Yokota
The Journal of Rheumatology February 2012, jrheum.110877; DOI: https://doi.org/10.3899/jrheum.110877
Masaaki Mori
Tomoyuki Imagawa
Ryoki Hara
Masako Kikuchi
Takuma Hara
Tomo Nozawa
Takako Miyamae
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Efficacy and Limitation of Infliximab Treatment for Children with Kawasaki Disease Intractable to Intravenous Immunoglobulin Therapy: Report of an Open-label Case Series
Masaaki Mori, Tomoyuki Imagawa, Ryoki Hara, Masako Kikuchi, Takuma Hara, Tomo Nozawa, Takako Miyamae, Shumpei Yokota
The Journal of Rheumatology Feb 2012, jrheum.110877; DOI: 10.3899/jrheum.110877
Efficacy and Limitation of Infliximab Treatment for Children with Kawasaki Disease Intractable to Intravenous Immunoglobulin Therapy: Report of an Open-label Case Series
Masaaki Mori, Tomoyuki Imagawa, Ryoki Hara, Masako Kikuchi, Takuma Hara, Tomo Nozawa, Takako Miyamae, Shumpei Yokota
The Journal of Rheumatology Feb 2012, jrheum.110877; DOI: 10.3899/jrheum.110877